Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Swedish Orphan Biovitrum AB Sweden

Rapid reduction in disease activity seen at 12 weeks sustained at one year55% of patients showed zero C3c staining intensity, indicating that C3c deposits clearedHighlighted as late-breaking oral presentation at the European Renal Association (ERA) CongressView original content:https://www.prnewswire.co.uk/news-releases/positive-data-from-phase-2-noble-study-of-pegcetacoplan-presented-as-late-breaker-at-era-congress-302155222.html